search
Back to results

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

Primary Purpose

Graft Versus Host Disease

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Natalizumab
Methylprednisolone
Sponsored by
Dana-Farber Cancer Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Graft Versus Host Disease focused on measuring Graft Versus Host Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participants must meet the following criteria on screening examination to be eligible to participate in the study:
  • Participants must have acute Graft-Versus-Host Disease (GVHD) of the lower gastrointestinal tract as defined by the clinical impression of the treating physician, requiring systemic treatment. Minimum criteria for GI GVHD includes diarrhea of greater than 500 mL/day. Biopsy of the GI tract is required for study entry and must confirm the diagnosis of acute GVHD. Stool samples to rule out infectious causes of diarrhea, including norovirus, Clostridium difficile and other clinically indicated infections must also be negative. Eligibility includes:
  • Acute GVHD developing after allogeneic hematopoietic stem cell transplantation (HSCT) using bone marrow, peripheral blood stem cells, or umbilical cord blood. Recipients of non-myeloablative, reduced intensity and myeloablative transplants are eligible.
  • Patients who develop acute GVHD after donor lymphocyte infusion (DLI) are eligible.
  • There is no specified time window after day 0 of transplant as acute GVHD is only defined by clinical manifestations.
  • Patients must have experienced neutrophil engraftment after HSCT as defined by absolute neutrophil counts ≥ 500 / µL × 3 consecutive measurements. Absolute neutrophil count (ANC) should be calculated using the standard formula (Neut + Bands)(WBC × 101).
  • The presence of hepatic, upper GI and/or cutaneous acute GVHD is permitted.
  • Steroids can be started up to 7 days prior to the administration of natalizumab.
  • Age ≥ 18
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

  • Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study:
  • Patients with the entity of Acute/Chronic GVHD overlap syndromes.
  • Requiring mechanical ventilation
  • Vasopressor requirement
  • Concurrent hepatic veno-occlusive disease (VOD) based on clinical examination
  • Karnofsky performance status < 30
  • Participants may not be receiving any other study agents for at least 7 days prior to enrollment
  • Prior use of natalizumab for any reason is not allowed
  • Pregnant women are excluded from this study because of the potential teratogenic effects of natalizumab. Because natalizumab enters breast milk, and the effect is unknown in infants, breastfeeding should be discontinued if the mother is treated with natalizumab.

Sites / Locations

  • Massachusetts General Hospital
  • Dana-Farber Cancer Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Natalizumab

Arm Description

Natalizumab- (Day 0 and 28) Fixed dose Intravenous infusion over one hour. 2 hours observation completion of the infusion At 4 weeks, if there has been less than a complete response participants can be treated with a second dose of natalizumab. If participants have no response after one dose, they will be not be given a second dose. Participants who receive a second dose of natalizumab will be evaluated for response at day 56 after first treatment dose administered. Participants will be assessed for response to therapy with natalizumab at day +28, day +56, day +100, day + 180, and day +365. Commercial supplies of Methylprednisolone (or equivalent steroid) will be utilized. The formulation, preparation and route of administration will be as per package insert

Outcomes

Primary Outcome Measures

GVHD-free Survival Rate
Graft-versus-host disease (GVHD) free survival is defined as achieving complete response without death or relapse or requiring secondary immunosuppressive therapy . Proportions are reported descriptively. GVHD-free survival was assessed using the Kaplan-Meier method.

Secondary Outcome Measures

Graft-verus-host Disease (GVHD) Response Rate
Complete Response (CR) is defined as resolution of all signs and symptoms of acute GVHD. Very Good Partial Response (VGPR) is defined by no rash or residual erythematous rash involving less than 25% of the body surface, and total serum bilirubin concentration less than 2 mg/dL or less than 25% of baseline at enrollment and tolerating food or enteral feeding, predominantly formed stools, no overt gastrointestinal bleeding or abdominal cramping, and no more than occasional nausea and vomiting. Partial Response (PR) is defined as an improvement of one stage in one or more organs without progression in any other organ. Non-response (NR) is defined as no reduction in any GVHD organ staging. Progression is defined as either new organ involvement on day +8 or thereafter, or increased organ specific symptoms sufficient to increase the organ stage by one or more or the initiation of an additional GVHD agent. Overall Response Rate (ORR) is the sum of CR, VGPR, and PR.
GI aGVHD Response Rate
Gastrointestinal (GI) acute graft-versus-host disease (GVHD) Response is defined by complete response, very good partial response, or partial response in signs and symptoms of GI aGVHD.
Overall Survival (OS) Rate
Overall survival (OS) is defined from the date of natalizumab infusion to death or censored at last clinical evaluation. OS was estimated using the Kaplan-Meier method.
Rate of GVHD Flares
Number of subjects who experienced graft-versus-host disease (GVHD) flares requiring therapy after initial complete response (CR) or partial response (PR) by day 28 after the first dose of Natalizumab.
Percentage Steroid Dose Was Reduced at Day 28, 56, and 100 in Comparison to Steroid Dose at First Administration of Natalizumab.
Median percentage steroid dose was reduced at Day 28, Day 56, and Day 100 in comparison to steroid dose at first administration of Natalizumab.

Full Information

First Posted
June 25, 2014
Last Updated
April 7, 2020
Sponsor
Dana-Farber Cancer Institute
Collaborators
Biogen
search

1. Study Identification

Unique Protocol Identification Number
NCT02176031
Brief Title
Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD
Official Title
Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract
Study Type
Interventional

2. Study Status

Record Verification Date
April 2020
Overall Recruitment Status
Completed
Study Start Date
January 2015 (undefined)
Primary Completion Date
February 2019 (Actual)
Study Completion Date
February 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Dana-Farber Cancer Institute
Collaborators
Biogen

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug Natalizumab in treating Acute Graft-Versus-Host Disease (GVHD) in the Gastrointestinal (GI) Tract.
Detailed Description
Natalizumab is a drug that was initially discovered as a treatment for autoimmune conditions. Natalizumab has been approved for use in patients with Multiple Sclerosis and Crohn's disease. In these diseases, the drug works to inhibit dysfunctional immune cells that are responsible for the symptoms seen in these diseases. Acute graft versus host disease is caused by a similar dysfunction of immune cells; Natalizumab is thought to inhibit these immune cells, similarly to how it does in Multiple Sclerosis and Crohn's disease. In this research study,the investigators are looking to see whether Natalizumab provides additional benefit to patients receiving standard treatment for acute graft versus host disease of the gastrointestinal tract. Participants who fulfill eligibility criteria will be entered into the trial to receive Natalizumab. Participant will receive a dose of the natalizumab through intravenous infusion. Participants may receive a second dose at Day 28 if they experience a partial response or very good partial response. Scheduled Physical Examination at screening, during the week of first dose and at 28 days, 56 days, 100 days, 180 days and one year.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Graft Versus Host Disease
Keywords
Graft Versus Host Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
21 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Natalizumab
Arm Type
Experimental
Arm Description
Natalizumab- (Day 0 and 28) Fixed dose Intravenous infusion over one hour. 2 hours observation completion of the infusion At 4 weeks, if there has been less than a complete response participants can be treated with a second dose of natalizumab. If participants have no response after one dose, they will be not be given a second dose. Participants who receive a second dose of natalizumab will be evaluated for response at day 56 after first treatment dose administered. Participants will be assessed for response to therapy with natalizumab at day +28, day +56, day +100, day + 180, and day +365. Commercial supplies of Methylprednisolone (or equivalent steroid) will be utilized. The formulation, preparation and route of administration will be as per package insert
Intervention Type
Drug
Intervention Name(s)
Natalizumab
Other Intervention Name(s)
Tysabri®
Intervention Type
Drug
Intervention Name(s)
Methylprednisolone
Other Intervention Name(s)
Steroid
Primary Outcome Measure Information:
Title
GVHD-free Survival Rate
Description
Graft-versus-host disease (GVHD) free survival is defined as achieving complete response without death or relapse or requiring secondary immunosuppressive therapy . Proportions are reported descriptively. GVHD-free survival was assessed using the Kaplan-Meier method.
Time Frame
Day 56
Secondary Outcome Measure Information:
Title
Graft-verus-host Disease (GVHD) Response Rate
Description
Complete Response (CR) is defined as resolution of all signs and symptoms of acute GVHD. Very Good Partial Response (VGPR) is defined by no rash or residual erythematous rash involving less than 25% of the body surface, and total serum bilirubin concentration less than 2 mg/dL or less than 25% of baseline at enrollment and tolerating food or enteral feeding, predominantly formed stools, no overt gastrointestinal bleeding or abdominal cramping, and no more than occasional nausea and vomiting. Partial Response (PR) is defined as an improvement of one stage in one or more organs without progression in any other organ. Non-response (NR) is defined as no reduction in any GVHD organ staging. Progression is defined as either new organ involvement on day +8 or thereafter, or increased organ specific symptoms sufficient to increase the organ stage by one or more or the initiation of an additional GVHD agent. Overall Response Rate (ORR) is the sum of CR, VGPR, and PR.
Time Frame
28 Days, 56 Days
Title
GI aGVHD Response Rate
Description
Gastrointestinal (GI) acute graft-versus-host disease (GVHD) Response is defined by complete response, very good partial response, or partial response in signs and symptoms of GI aGVHD.
Time Frame
Day 28, Day 56
Title
Overall Survival (OS) Rate
Description
Overall survival (OS) is defined from the date of natalizumab infusion to death or censored at last clinical evaluation. OS was estimated using the Kaplan-Meier method.
Time Frame
2 years
Title
Rate of GVHD Flares
Description
Number of subjects who experienced graft-versus-host disease (GVHD) flares requiring therapy after initial complete response (CR) or partial response (PR) by day 28 after the first dose of Natalizumab.
Time Frame
by Day 28
Title
Percentage Steroid Dose Was Reduced at Day 28, 56, and 100 in Comparison to Steroid Dose at First Administration of Natalizumab.
Description
Median percentage steroid dose was reduced at Day 28, Day 56, and Day 100 in comparison to steroid dose at first administration of Natalizumab.
Time Frame
Day 28, 56, and 100

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants must meet the following criteria on screening examination to be eligible to participate in the study: Participants must have acute Graft-Versus-Host Disease (GVHD) of the lower gastrointestinal tract as defined by the clinical impression of the treating physician, requiring systemic treatment. Minimum criteria for GI GVHD includes diarrhea of greater than 500 mL/day. Biopsy of the GI tract is required for study entry and must confirm the diagnosis of acute GVHD. Stool samples to rule out infectious causes of diarrhea, including norovirus, Clostridium difficile and other clinically indicated infections must also be negative. Eligibility includes: Acute GVHD developing after allogeneic hematopoietic stem cell transplantation (HSCT) using bone marrow, peripheral blood stem cells, or umbilical cord blood. Recipients of non-myeloablative, reduced intensity and myeloablative transplants are eligible. Patients who develop acute GVHD after donor lymphocyte infusion (DLI) are eligible. There is no specified time window after day 0 of transplant as acute GVHD is only defined by clinical manifestations. Patients must have experienced neutrophil engraftment after HSCT as defined by absolute neutrophil counts ≥ 500 / µL × 3 consecutive measurements. Absolute neutrophil count (ANC) should be calculated using the standard formula (Neut + Bands)(WBC × 101). The presence of hepatic, upper GI and/or cutaneous acute GVHD is permitted. Steroids can be started up to 7 days prior to the administration of natalizumab. Age ≥ 18 Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study: Patients with the entity of Acute/Chronic GVHD overlap syndromes. Requiring mechanical ventilation Vasopressor requirement Concurrent hepatic veno-occlusive disease (VOD) based on clinical examination Karnofsky performance status < 30 Participants may not be receiving any other study agents for at least 7 days prior to enrollment Prior use of natalizumab for any reason is not allowed Pregnant women are excluded from this study because of the potential teratogenic effects of natalizumab. Because natalizumab enters breast milk, and the effect is unknown in infants, breastfeeding should be discontinued if the mother is treated with natalizumab.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Corey Cutler, MD, MPH
Organizational Affiliation
Dana-Farber Cancer Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

We'll reach out to this number within 24 hrs